Lorenzo Bertani, UEG Week 2022: IL-23 serum levels for the prediction of therapeutic response to ustekinumab in Crohn’s disease

Ustekinumab is a human interleukin-12 and -23 antagonist approved for the treatment of Crohn’s disease. touchIMMUNOLOGY were delighted to talk with Dr. Lorenzo Bertani (University of Pisa, Pisa, Italy) to discuss the rationale, methodology and findings from his study investiagting whether baseline IL-23 serum levels could predict therapeutic response to ustekinumab.

The abstract entitled ‘BASELINE IL-23 SERUM LEVELS PREDICT THERAPEUTIC RESPONSE TO USTEKINUMAB THERAPY IN CROHN’S DISEASE. A PROSPECTIVE STUDY’ was presented at UEG Week, October 8 – 11, 2022.

Questions

1. What has been the impact of ustekinumab on the treatment of Crohn’s disease and what are its limitations? (0:16)
2. What was the rationale for the study you are presenting? (1:01)
3. What were the methodology and clinical endpoints of the study? (1:55)
4. What factors were found to predict therapeutic response to ustekinumab? (3:01)
5. What questions remain unanswered, and what future studies are planned? (4:11)

Disclosures: Lorenzo Bertani has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed as a highlight of UEG Week 2022.